Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) is 8.14% higher on its value in year-to-date trading and has touched a low of $16.56 and a high of $28.15 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KNSA stock was last observed hovering at around $21.33 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $21.39, the stock is 7.09% and 8.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.24 million and changing 0.28% at the moment leaves the stock -3.19% off its SMA200. KNSA registered -1.61% loss for a year compared to 6-month loss of -20.01%.
The stock witnessed a 13.29% gain in the last 1 month and extending the period to 3 months gives it a -3.12%, and is 8.63% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.20% over the week and 4.30% over the month.
Kiniksa Pharmaceuticals International Plc (KNSA) has around 315 employees, a market worth around $1.55B and $423.24M in sales. Fwd P/E is 19.52. Profit margin for the company is -10.21%. Distance from 52-week low is 29.17% and -24.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-9.68%).
The EPS is expected to grow by 195.00% this year
The shares outstanding are 41.88M, and float is at 40.16M with Short Float at 7.37%.
The top institutional shareholder in the company is BARCLAYS PLC with over 34839.0 shares valued at $0.65 million. The investor’s holdings represent 0.0493 of the KNSA Shares outstanding. As of 2024-06-30, the second largest holder is BIRCHVIEW CAPITAL, LP with 30000.0 shares valued at $0.56 million to account for 0.0425 of the shares outstanding. The other top investors are ADIRONDACK TRUST CO which holds 875.0 shares representing 0.0012 and valued at over $16266.0, while ADVISOR GROUP HOLDINGS, INC. holds 0.0009 of the shares totaling 623.0 with a market value of $11631.0.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider Activity
The most recent transaction is an insider sale by Tessari Eben, the company’s CHIEF OPERATING OFFICER. SEC filings show that Tessari Eben sold 14,000 shares of the company’s common stock on Feb 10 ’25 at a price of $19.57 per share for a total of $0.27 million. Following the sale, the insider now owns 81975.0 shares.
Still, SEC filings show that on Jan 13 ’25, Tessari Eben (CHIEF OPERATING OFFICER) disposed off 14,000 shares at an average price of $18.24 for $0.26 million. The insider now directly holds 88,975 shares of Kiniksa Pharmaceuticals International Plc (KNSA).
Kiniksa Pharmaceuticals International Plc (KNSA): Who are the competitors?
One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 19.23% up over the past 12 months.Johnson & Johnson (JNJ) lies in the list of competitors of the Kiniksa Pharmaceuticals International Plc and is 3.63% higher over the same period from KNSAAbbVie Inc. (ABBV) is 16.83% up on the 1-year trading charts.
